Skip to content

Semantic Analysis by spaCy

Merck Kgaa Vs. Integra Lifesciences I, Ltd.

Decided On : Jun-13-2005

Court : US Supreme Court

Notice (8): Undefined index: topics [APP/View/Case/meta.ctp, line 36]
Warning (2): Invalid argument supplied for foreach() [APP/View/Case/meta.ctp, line 39]

ORG: Merck, SUPREME COURT, the united states court of appeals, Federal, The Federal Food, Drug, FDCA, the Food and Drug Administration, FDA, IND, NDA, RGD, the District Court, The Federal Circuit, the District Court’s, FDA, IND, NDA, FDCA, Eli Lilly & Co., Medtronic, Inc., FDA, FDA, FDA, FDA, the Federal Circuit, Court, SUPREME COURT, the united states court of appeals, Court, the Food and Drug Administration, FDA, Congress, Drug Price Competition and Patent Term Restoration Act, the Federal Food, Drug, Federal, The Federal Food, Drug, Eli Lilly & Co., Medtronic, Inc., FDCA, FDA, IND, IND, CFR §§312.23(a)(5, NDA, FDA, NDA, CFR §§314.50(d)(2, the Burnham Institute, RGD, Supp, RGD, CA Fed, the Scripps Research Institute, Scripps, Telios Pharmaceuticals, CV–1307, LM609, RGD, See Altman, Brooks, Cheresh, Scripps, Scripps, RGD, Scripps, IND, FDA, Scripps, Scripps, RGD, FDA, CFR §312.23(a)(8)(iii, Scripps, CV–1307, RGD, Scripps, Scripps, LM609, Scripps, RGD, Scripps, RGD, RGD, CV–1307, FDA, RGD, the National Cancer Institute, NCI, NCI, IND, Scripps, the District Court, RGD, Scripps, Scripps, RGD, Scripps, RGD, the District Court, RGD, RGD, the District Court, Scripps, FDA, FDA, Scripps, the District Court, Scripps, the District Court, Scripps, FDA, the Court of Appeals, the Federal Circuit, Scripps, FDA, the District Court’s, the District Court’s, RGD, the Court of Appeals, Federal, FDCA, Eli Lilly, FDA, FDA, IND, NDA, FDA, IND, FDA, FDA, IND, Department of Health and Human Services, Guidance for Industry, Good Clinical Practice, FDA, CFR, the Institutional Review Boards, FDA, FDA, FDA, IND, FDA, FDA, FDA, CFR §, CFR §58.1(a, FDA, IND, The Court of Appeals, RGD, Scripps, the “, Scripps-Merck, FDA, FDA, FDA, FDA, FDA, Scripps, FDA, FDA, FDA, FDA, FDA, the Court of Appeals, IND, FDA, Congress, FDA, Eli Lilly, FDA, FDA, FDA, FDA, FDA, IND, NDA, District Court, FDA, Ventritex, Inc., aff’d, CA Fed, FDA, IND, CFR §, Government, IND, NDA, the Court of Appeals, the Court of Appeals, FDA, the Court of Appeals, RGD, CA Fed, Scripps, Scripps, IND, FDA, the District Court, the Court of Appeals, The Court of Appeals, IND, IND, The Court of Appeals, RGD, Scripps, Newman, FDA, FDA, IND, NDA

PERSON: Integra Lifesciences, al, certiorari, Scalia, J., Merck KGaA, Integra Lifesciences, al, Scalia, Arg-Gly-Asp, Merck KGaA, David Cheresh, al, Merck KGaA, al, App, Cheresh, Cheresh, Cheresh, N. Y. Times, Brooks, Integrin, Clark, Cheresh, Petitioner’s, Cheresh, Cheresh, Newman, J., Cheresh, Cheresh, Cheresh, Cheresh, Cheresh, App, Cert, App, Cert, Newman, Newman, J., Cheresh, Cheresh, J.

DATE: 2005, OCTOBER TERM,, 2004, April 20, 2005, June 13, 2005 , 1938, 2005, 2005, June 13, 2005, 1984, 1984, 1585, March 4, 1913, 1040, 1990, 2005, 2003, 1988, Sept. 9, 1997, 1994, Dec. 30, 1994, 1157, Dec. 30, 1994, Apr. 22, 1994, July 1995, February 1, 1995, 3-year, 105a, year one, year three, February 20, 1995, April 13, 1995, three years, 126a, April 13, 2005, 2004, September 1995, 31a, 1995, 1998, 1997, the same period, November 1996, April 1997, 31a, October 1998, 1998, July 18, 1996, pre-1995, 1995, 57a, Mar. 26, 2001, 52a, Mar. 6, 2001, 50a, 49a, 2004, 2005, Apr. 1996, 2005, 2004, 2005, 1269, 1280, 1991, 1993, 23, today, 2003, December 30, 1996, February 1997, CV 1307–B(AJB, 2004, 2284001, Sept. 7, 2004, 57a

GPE: the United States, Pp., THE UNITED STATES, the United States, the United States, d)(5, al., Angiogenesis, Id., the United States, Id., Id., Id., California, Id., Id., Id., the United States, United States, §312.23(a)(8)(iii, Id., United States, Ixsys, California, Ixsys, Vitaxin, Id., Id., Id.

PERCENT: 35 U. S. C. §271(e)(1, 496 U. S., 545 U. S., 35 U. S. C. §, 35 U. S. C. §271(e)(1, 21 U. S. C. §301, 496 U. S., 21 U. S. C. §355(i)(1)(A, 21 U. S. C. §355(b)(1, 35 U. S. C. §271(e)(1, 35 U. S. C. §, 496 U. S., 21 U. S. C. §355(i)(3)(B)(i, 496 U. S.

NORP: §, §, §, §, §, d., d., d., d., d., d., §, §, §, §, d., §, §, §, §, §, §, §, §, §, §, §, §, §, §

CARDINAL: 665–669, 03-1237, 202, 98, 675, 52, 665–666, 674, two, 21, 21, 21, five, 4,988,621, 4,792,525, 5,695,997, 4,879,237, 4,789,734, 3, 331, 862–863, 96, 30a, 331, 863, 3, A1, 3, 79, 3, 264, 569, 127a, 21, 96, two, 331, 863, 285a–298a, 3, 223a–224a, 188a, 96, 397a, 214a–217a, 331, 874, 863, 863, one, 866, 872, 874, 877, 868–869, 873, 543, 665–669, 21, 312.23(a)(5, 21, 10, 43, at least two, 21, 21, 58, two, 865, 866, 867, 1, 2, One, 674, 775, 991, 21, 312.22(b, 355(j)(2)(A, 355(j)(8)(B, 3, 331, 869, 271a–274a, 399a–404a, 304a, 1, 6, 331, 866, 878

QUANTITY: 331 F. 3d 860, 331 F. 3d, 331 F. 3d, 331 F. 3d

EVENT: Cosmetic Act, EMD 66203

ORDINAL: First, Second, first, First, Second, First, Second, first, first

MONEY: $6 million, $15 million, $6.375 million

LOC: Europe, the Southern District, I]t

PRODUCT: 271a, 404a

View Full Judgment


Save Judgments// Add Notes // Store Search Result sets // Organize Client Files //